SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing significant market interest following a series of strategic expansion announcements, including a major commitment to building autonomous vehicle charging infrastructure and new partnerships to integrate ride-hailing services. The community is actively debating the stock's long-term valuation versus its recent price volatility, with many investors highlighting substantial insider buying and institutional backing as signs of a potential bottom.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining market attention as investors weigh the recent Astria Therapeutics acquisition against high short interest and upcoming clinical data presentations at the AAAAI meeting. The community is actively debating the company's path to profitability and whether the pipeline progress, particularly regarding navenibart, will finally catalyze a significant breakout in share price.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics is gaining significant market attention following a strategic equity offering that extends its cash runway and strengthens its balance sheet to support ongoing clinical milestones into 2027. Investors and community members are actively debating the impact of this capital raise, with many interpreting the participation of high-profile institutional entities as a vote of confidence in the company's proprietary radiopharmaceutical platform and its potential as a prime buyout target.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan D. Green on March 5, 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is currently a focal point for investors as the community debates its valuation and potential for an acquisition or share buyback following a recent earnings report that sparked significant volatility. Traders are closely tracking the stock's performance relative to Uber, with intense discussions around the impact of autonomous vehicle partnerships and the company's long-term profitability metrics.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid intense debate over the proposed Digital Asset Market Clarity Act, with the community split between bullish sentiment fueled by institutional partnership speculation and skepticism from those concerned about price manipulation. Traders are closely monitoring the token's correlation with broader market movements and its ability to maintain support levels as discussions around global adoption and potential regulation intensify.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is capturing significant trader attention as investors monitor its recent strategic acquisition of DTR and potential integration with institutional digital asset infrastructure. While many in the community remain divided between optimistic technical momentum plays and concerns over share dilution, active discussions are focused on how the company's evolving neobanking strategy and upcoming investor events may influence its performance in the shifting regulatory landscape.

Semtech Corp. engages in the manufacture and supply of analog and mixed signal semiconductor products for high-end consumer, enterprise computing, communications, and industrial equipment. The firm operates through the following business segments: Protection, Signal Integrity, and Wireless & Sensing. It offers signal integrity, protection, wireless and sensing, and power and high-reliability products. The company was founded in 1960 and is headquartered in Camarillo, CA.

Semtech Corp.

Semtech is facing intense volatility and downward pressure following significant guidance adjustments, fueling a fierce battle between retail bulls hunting for a short squeeze and bearish traders citing concerns over inventory and market headwinds. Investors are currently hyper-focused on the company's long-term potential in data center connectivity and AI infrastructure versus the immediate technical damage caused by recent, sharp price declines.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is trending heavily after announcing positive Phase 1 expansion data for its EpCAM PROBODY ADC, Varsetatug Masetecan, in patients with late-line colorectal cancer. The community is actively debating the stock's significant price surge and high volume, with investors weighing the clinical trial success against concerns about potential future dilution and the company's financial results.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is trending as investors closely watch for the announcement of a major tenant for its digital infrastructure projects, with sentiment currently driven by a mix of high-stakes anticipation and skepticism regarding management's project timelines. The community is actively debating the company's growth potential versus concerns over potential dilution and the lack of a finalized contract, while many traders remain focused on the stock's high volatility and its correlation with broader data center and energy sector momentum.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is seeing a surge in investor attention driven by strong momentum in its ADHD therapeutic pipeline, specifically the upcoming PDUFA decision for CTx-1301 and anticipation surrounding US patent developments. The community is actively discussing the stock's low-float setup, recent insider and institutional positioning, and the potential for a significant revaluation as the company advances toward its commercial launch.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PRTC PureTech Health presents deupirfenidone data at ATS conference 
 
PureTech Health delivered a late-breaking, oral presentation at the 2025 American Thoracic Society international conference in San Francisco. The presentation provided further insights into the Phase 2b ELEVATE IPF trial of deupirfenidone, highlighting the strength and durability of deupirfenidone&#39;s treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis. Data presented from PureTech&#39;s global Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging ELEVATE IPF trial demonstrated the potential for deupirfenidone to offer a differentiated treatment option for patients with IPF.  
 
In the trial, patients treated with deupirfenidone 825 mg three times a day experienced a slower rate of lung function decline, as measured by Forced Vital Capacity, at 26 weeks versus those who were treated with placebo. This statistically significant difference represents a robust treatment effect versus placebo of 80.9% for deupirfenidone 825 mg TID as a monotherapy. This result compares favorably against the rate of decline in FVC observed in the trial among patients treated with pirfenidone 801 mg TID versus placebo, which was consistent with previously reported pirfenidone clinical trial data and represents a treatment effect of 54.1%.  
 
Taken together, these results indicate that the treatment effect with deupirfenidone 825 mg TID was approximately 50% greater than that of pirfenidone 801 mg TID, based on their respective reductions in lung function decline versus placebo. In addition to these findings, deupirfenidone 825 mg TID also demonstrated a statistically significant benefit in delaying time to IPF progression4 compared to placebo, further supporting the clinical relevance of the treatment effect. Importantly, the rate of FVC decline observed over 26 weeks with deupirfenidone 825 mg TID was similar to the expected natural decline in lung function in healthy older adults. Furthermore, preliminary data from the ongoing open-label extension study suggest that this treatment effect is durable out to at least 52 weeks.  
 
As of May 9, a total of 101 patients had received at least 52 weeks of treatment with deupirfenidone. Those in the deupirfenidone 825 mg TID arm experienced a decline in FVC of -32.8 mL over the 52-week period, which is similar to the expected natural decline in lung function in healthy older adults over one year. These new data provide additional support for the durability of the treatment effect observed with this dose and reinforce its potential to stabilize lung function decline over time, while maintaining favorable safety and tolerability. Additional details from the ongoing OLE are expected to be shared in a future scientific forum. These results are further supported by preliminary pharmacokinetic data, which underscore the differentiated profile of deupirfenidone.  
 
Compared to pirfenidone 801 mg TID, deupirfenidone 825 mg TID resulted in an approximately 50% increase in drug exposure. Notably, the dramatically increased drug exposure did not result in an increase in tolerability challenges, suggesting that the deuterated structure of deupirfenidone may overcome the dose-limiting adverse events associated with pirfenidone. PureTech believes these PK results are consistent with the enhanced efficacy and favorable tolerability seen with deupirfenidone 825 mg TID in the trial. Deupirfenidone was well tolerated at both doses studied. Safety analyses included identification of the 16 most common treatment-emergent adverse events, defined as occurring in more than 5% of participants in at least one treatment group, and characterized the arm with the highest relative incidence of each of these 16 TEAEs.  
 
The pirfenidone 801 mg treatment group had the highest relative incidence for 9 of these TEAEs, followed by deupirfenidone 825 mg (5), placebo (2), and deupirfenidone 550 mg. PureTech is targeting a meeting with the U.S. Food and Drug Administration by the end of the third quarter of 2025 to discuss the results of the Phase 2b trial and align on a potential registrational pathway, with the goal of initiating a Phase 3 trial by the end of 2025. PureTech anticipates providing further guidance later this year following the finalization of the trial design and FDA interactions.

StockTwits Web

Puretech Health

 PureTech Health presents deupirfenidone data at ATS conference 
 
PureTech Health delivered a late-breaking, oral presentation at the 2025 American Thoracic Society international conference in San Francisco. The presentation provided further insights into the Phase 2b ELEVATE IPF trial of deupirfenidone, highlighting the strength and durability of deupirfenidone's treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis. Data presented from PureTech's global Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging ELEVATE IPF trial demonstrated the potential for deupirfenidone to offer a differentiated treatment option for patients with IPF.  
 
In the trial, patients treated with deupirfenidone 825 mg three times a day experienced a slower rate of lung function decline, as measured by Forced Vital Capacity, at 26 weeks versus those who were treated with placebo. This statistically significant difference represents a robust treatment effect versus placebo of 80.9% for deupirfenidone 825 mg TID as a monotherapy. This result compares favorably against the rate of decline in FVC observed in the trial among patients treated with pirfenidone 801 mg TID versus placebo, which was consistent with previously reported pirfenidone clinical trial data and represents a treatment effect of 54.1%.  
 
Taken together, these results indicate that the treatment effect with deupirfenidone 825 mg TID was approximately 50% greater than that of pirfenidone 801 mg TID, based on their respective reductions in lung function decline versus placebo. In addition to these findings, deupirfenidone 825 mg TID also demonstrated a statistically significant benefit in delaying time to IPF progression4 compared to placebo, further supporting the clinical relevance of the treatment effect. Importantly, the rate of FVC decline observed over 26 weeks with deupirfenidone 825 mg TID was similar to the expected natural decline in lung function in healthy older adults. Furthermore, preliminary data from the ongoing open-label extension study suggest that this treatment effect is durable out to at least 52 weeks.  
 
As of May 9, a total of 101 patients had received at least 52 weeks of treatment with deupirfenidone. Those in the deupirfenidone 825 mg TID arm experienced a decline in FVC of -32.8 mL over the 52-week period, which is similar to the expected natural decline in lung function in healthy older adults over one year. These new data provide additional support for the durability of the treatment effect observed with this dose and reinforce its potential to stabilize lung function decline over time, while maintaining favorable safety and tolerability. Additional details from the ongoing OLE are expected to be shared in a future scientific forum. These results are further supported by preliminary pharmacokinetic data, which underscore the differentiated profile of deupirfenidone.  
 
Compared to pirfenidone 801 mg TID, deupirfenidone 825 mg TID resulted in an approximately 50% increase in drug exposure. Notably, the dramatically increased drug exposure did not result in an increase in tolerability challenges, suggesting that the deuterated structure of deupirfenidone may overcome the dose-limiting adverse events associated with pirfenidone. PureTech believes these PK results are consistent with the enhanced efficacy and favorable tolerability seen with deupirfenidone 825 mg TID in the trial. Deupirfenidone was well tolerated at both doses studied. Safety analyses included identification of the 16 most common treatment-emergent adverse events, defined as occurring in more than 5% of participants in at least one treatment group, and characterized the arm with the highest relative incidence of each of these 16 TEAEs.  
 
The pirfenidone 801 mg treatment group had the highest relative incidence for 9 of these TEAEs, followed by deupirfenidone 825 mg (5), placebo (2), and deupirfenidone 550 mg. PureTech is targeting a meeting with the U.S. Food and Drug Administration by the end of the third quarter of 2025 to discuss the results of the Phase 2b trial and align on a potential registrational pathway, with the goal of initiating a Phase 3 trial by the end of 2025. PureTech anticipates providing further guidance later this year following the finalization of the trial design and FDA interactions.